Literature DB >> 32145215

Identification of the hyper-variable genomic hotspot for the novel coronavirus SARS-CoV-2.

Feng Wen1, Hai Yu2, Jinyue Guo3, Yong Li4, Kaijian Luo5, Shujian Huang6.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32145215      PMCID: PMC7126159          DOI: 10.1016/j.jinf.2020.02.027

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


× No keyword cloud information.

Dear editor

A recent study in this journal studied the genomes of the novel SARS-like coronavirus (SARS-CoV-2) in China and suggested that the SARS-CoV-2 had undergone genetic recombination with SARS-related CoV. By February 14, 2020, a total of 66,576 confirmed cases of COVID-19, people infected with SARS-CoV-2, were reported in China, leading to 1524 deaths, per the Chinese CDC (http://2019ncov.chinacdc.cn/2019-nCoV/). Several full genomic sequences of this virus have been released for the study of its evolutionary origin and molecular characteristics2, 3, 4. Here, we analyzed the potential mutations that may have evolved after the virus became epidemic among humans and also the mutations resulting in the human adaptation. The sequences of BetaCoV were downloaded on February 3, 2020 from the GISAID platform. A total of 58 accessions were available, among which BetaCoV/bat/Yunnan/RaTG13/2013 is a known close relative of SARS-CoV-2. Four accessions, namely, BetaCov/Italy/INM1/2020, BetaCov/Italy/INM2/2020, BetaCoV/Kanagawa/1/2020, and BetaCoV/USA/IL1/2020, were excluded because of the short-truncated sequences or multiple ambiguous nucleotides. A total of 54 accessions (Supplementary Table 1) isolated from humans were utilized in the following analysis. The sequences NC_004718.3 of SARS coronavirus genes were utilized to define the protein products of SARS-CoV-2. The protein sequences of ORF1ab, S, E, M, and N genes were translated, and all of the loci without experimental evidences were excluded. First, the protein sequences of SARS-CoV-2 were compared with RaTG13, human SARS (NC_004718.3), bat SARS (DQ022305.2), and human MERS (NC_019843.3) by calculating the similarity in a given sliding window (Fig. 1 A). The sliding window was set to 500 for ORF1ab and S, and to 50 for proteins E, M, and N considering their short length. SARS-CoV-2 were highly similar to RaTG13 isolated from bats, showing 96% identity based on the whole-nucleotide sequences and 83% based on the protein sequences, suggesting a bat zoonotic origin of SARS-CoV-2. ORF1a, and the head of S seemed to have diverged from other beta coronaviruses.
Fig. 1

(A) The similarity between SARS-CoV-2 and other beta coronaviruses using the sliding window showed that SARS-CoV-2 was similar to bat virus RaTG13. (B) The molecular phylogenetic tree based on protein sequences established the high similarity among SARS-CoV-2 and its near relatives. (C) The mutations that developed after it came to circulate among humans did not include any mutation with high occurrence. (D) The graphs show all of the differences between SARS-CoV-2 and its close relative strains isolated from bats.

(A) The similarity between SARS-CoV-2 and other beta coronaviruses using the sliding window showed that SARS-CoV-2 was similar to bat virus RaTG13. (B) The molecular phylogenetic tree based on protein sequences established the high similarity among SARS-CoV-2 and its near relatives. (C) The mutations that developed after it came to circulate among humans did not include any mutation with high occurrence. (D) The graphs show all of the differences between SARS-CoV-2 and its close relative strains isolated from bats. The molecular phylogenetic tree (Fig. 1B) was built by using the maximum likelihood method based on the JTT matrix-based model. It hinted that the protein sequences of SARS-CoV-2 had over 99% similarity. Twenty-eight viruses had shared the same protein sequences, and could be the original strain circulated in the humans. The other viruses had only a few mutations from it. This indicates that the virus could have evolved for only a very short time after gaining the efficient human to human transmissibility, as expected. Next, we analyzed the mutations that occurred after infecting humans (Fig. 1C) in order to identify mutations associated with more severe infection. Here, two accessions (BetaCoV/Shenzhen/SZTH-001/2020 and BetaCoV/Shenzhen/SZTH-004/2020) from Shenzhen, which had 5 and 16 mutations, respectively, were excluded, considering the possible experimental issues. All of the mutations only occurred once, so it is possible that all of these mutations occur naturally and are associated with viral survival and infection. Several mutations were clustered in peptides nsp3 and nsp4 of ORF1ab and in the header of S. These results suggested that there had probably been no hyper-variable genomic hotspot in the SARS-CoV-2 population until now. We compared these results with those of the work of Ceraolo and Giorgi, who reported at least two hyper-variable genomic hotspots based on the Shannon entropy of nucleotide sequences. They utilized all of the sequences, while we merged all of the fully identical sequences into one during our Shannon entropy calculation. As shown in Fig. 1B, 28 sequences were merged into one in present study because they had been collected in such a short time, so collection time and location could not have produced any large bias. If those identical sequences were calculated individually, any mutations on these 28 sequences would have sharply increased Shannon entropy. The protein sequences were used to exclude any unimportant silent mutations. Finally, the sequences of earliest SARS-CoV-2 were compared with RaTG13 from bats (Fig. 1D). Fisher's exact test with post hoc test suggested that nsp1, nsp3, and nsp15 of ORF1ab and gene S had significantly more mutations than other genes, which might facilitate human adaptation and infection. S gene encodes spike glycoprotein, which binds host ACE2 receptors and is required for initiation of the infection. They reported that a 193-amino acid fragment was able to bind ACE2 more efficiently than its unmutated counterpart. This region in which spike glycoprotein binds to ACE2 had 21 mutations not found in RaTG13, suggesting their role in the adaptation to human hosts. Peptide nsp1 facilitated viral gene expression and evasion from the host immune response. Peptide nsp3, named papain-like proteinase, was found to be associated with the cleavages, viral replication, and antagonization of innate immune. These two peptides are probably associated with the latent period after infection in humans. Peptide nsp15 acted as uridylate-specific endoribonuclease. These results collectively suggest that peptides nsp1, nsp3, and nsp15 might have unclear but critical roles in this outbreak of SARS-CoV-2. To summarize, this study confirmed the relationship of SARS-CoV-2 with other beta coronaviruses on the amino acid level. The hyper-variable genomic hotspot has been established in the SARS-CoV-2 population at the nucleotide but not the amino acid level, suggesting that there have been no beneficial mutations. The mutations in nsp1, nsp3, nsp15, and gene S that identified in this study would be associated with the SARS-CoV-2 epidemic and was worthy of further study.

Declaration of Competing Interest

None.
  10 in total

1.  The rapid generation of mutation data matrices from protein sequences.

Authors:  D T Jones; W R Taylor; J M Thornton
Journal:  Comput Appl Biosci       Date:  1992-06

2.  Severe acute respiratory syndrome coronavirus protein nsp1 is a novel eukaryotic translation inhibitor that represses multiple steps of translation initiation.

Authors:  Kumari G Lokugamage; Krishna Narayanan; Cheng Huang; Shinji Makino
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

3.  The Genome sequence of the SARS-associated coronavirus.

Authors:  Marco A Marra; Steven J M Jones; Caroline R Astell; Robert A Holt; Angela Brooks-Wilson; Yaron S N Butterfield; Jaswinder Khattra; Jennifer K Asano; Sarah A Barber; Susanna Y Chan; Alison Cloutier; Shaun M Coughlin; Doug Freeman; Noreen Girn; Obi L Griffith; Stephen R Leach; Michael Mayo; Helen McDonald; Stephen B Montgomery; Pawan K Pandoh; Anca S Petrescu; A Gordon Robertson; Jacqueline E Schein; Asim Siddiqui; Duane E Smailus; Jeff M Stott; George S Yang; Francis Plummer; Anton Andonov; Harvey Artsob; Nathalie Bastien; Kathy Bernard; Timothy F Booth; Donnie Bowness; Martin Czub; Michael Drebot; Lisa Fernando; Ramon Flick; Michael Garbutt; Michael Gray; Allen Grolla; Steven Jones; Heinz Feldmann; Adrienne Meyers; Amin Kabani; Yan Li; Susan Normand; Ute Stroher; Graham A Tipples; Shaun Tyler; Robert Vogrig; Diane Ward; Brynn Watson; Robert C Brunham; Mel Krajden; Martin Petric; Danuta M Skowronski; Chris Upton; Rachel L Roper
Journal:  Science       Date:  2003-05-01       Impact factor: 47.728

4.  GISAID: Global initiative on sharing all influenza data - from vision to reality.

Authors:  Yuelong Shu; John McCauley
Journal:  Euro Surveill       Date:  2017-03-30

5.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

6.  Genomic variance of the 2019-nCoV coronavirus.

Authors:  Carmine Ceraolo; Federico M Giorgi
Journal:  J Med Virol       Date:  2020-02-19       Impact factor: 2.327

7.  Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China.

Authors:  Aiping Wu; Yousong Peng; Baoying Huang; Xiao Ding; Xianyue Wang; Peihua Niu; Jing Meng; Zhaozhong Zhu; Zheng Zhang; Jiangyuan Wang; Jie Sheng; Lijun Quan; Zanxian Xia; Wenjie Tan; Genhong Cheng; Taijiao Jiang
Journal:  Cell Host Microbe       Date:  2020-02-07       Impact factor: 21.023

8.  A new coronavirus associated with human respiratory disease in China.

Authors:  Fan Wu; Su Zhao; Bin Yu; Yan-Mei Chen; Wen Wang; Zhi-Gang Song; Yi Hu; Zhao-Wu Tao; Jun-Hua Tian; Yuan-Yuan Pei; Ming-Li Yuan; Yu-Ling Zhang; Fa-Hui Dai; Yi Liu; Qi-Min Wang; Jiao-Jiao Zheng; Lin Xu; Edward C Holmes; Yong-Zhen Zhang
Journal:  Nature       Date:  2020-02-03       Impact factor: 49.962

9.  The continuous evolution and dissemination of 2019 novel human coronavirus.

Authors:  Jiahao Zhang; Kaixiong Ma; Huanan Li; Ming Liao; Wenbao Qi
Journal:  J Infect       Date:  2020-02-22       Impact factor: 6.072

10.  A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.

Authors:  Swee Kee Wong; Wenhui Li; Michael J Moore; Hyeryun Choe; Michael Farzan
Journal:  J Biol Chem       Date:  2003-12-11       Impact factor: 5.157

  10 in total
  16 in total

1.  Stability of SARS-CoV-2 phylogenies.

Authors:  Yatish Turakhia; Nicola De Maio; Bryan Thornlow; Landen Gozashti; Robert Lanfear; Conor R Walker; Angie S Hinrichs; Jason D Fernandes; Rui Borges; Greg Slodkowicz; Lukas Weilguny; David Haussler; Nick Goldman; Russell Corbett-Detig
Journal:  PLoS Genet       Date:  2020-11-18       Impact factor: 5.917

Review 2.  Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm.

Authors:  Ali A Rabaan; Shamsah H Al-Ahmed; Javed Muhammad; Amjad Khan; Anupam A Sule; Raghavendra Tirupathi; Abbas Al Mutair; Saad Alhumaid; Awad Al-Omari; Manish Dhawan; Ruchi Tiwari; Khan Sharun; Ranjan K Mohapatra; Saikat Mitra; Muhammad Bilal; Salem A Alyami; Talha Bin Emran; Mohammad Ali Moni; Kuldeep Dhama
Journal:  Vaccines (Basel)       Date:  2021-04-29

3.  Coronaviruses' sugar shields as vaccine candidates.

Authors:  Denong Wang
Journal:  Curr Trends Immunol       Date:  2020

Review 4.  Immune Response, Inflammation, and the Clinical Spectrum of COVID-19.

Authors:  Luis F García
Journal:  Front Immunol       Date:  2020-06-16       Impact factor: 7.561

Review 5.  Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery.

Authors:  P Chellapandi; S Saranya
Journal:  Med Chem Res       Date:  2020-07-31       Impact factor: 2.351

Review 6.  Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view.

Authors:  J M Abduljalil; B M Abduljalil
Journal:  New Microbes New Infect       Date:  2020-03-31

Review 7.  Studying SARS-CoV-2 infectivity and therapeutic responses with complex organoids.

Authors:  Kevin G Chen; Kyeyoon Park; Jason R Spence
Journal:  Nat Cell Biol       Date:  2021-08-02       Impact factor: 28.824

8.  Genetic variants and source of introduction of SARS-CoV-2 in South America.

Authors:  Julio A Poterico; Orson Mestanza
Journal:  J Med Virol       Date:  2020-07-19       Impact factor: 20.693

9.  Large scale genomic analysis of 3067 SARS-CoV-2 genomes reveals a clonal geo-distribution and a rich genetic variations of hotspots mutations.

Authors:  Meriem Laamarti; Tarek Alouane; Souad Kartti; M W Chemao-Elfihri; Mohammed Hakmi; Abdelomunim Essabbar; Mohamed Laamarti; Haitam Hlali; Houda Bendani; Nassma Boumajdi; Oussama Benhrif; Loubna Allam; Naima El Hafidi; Rachid El Jaoudi; Imane Allali; Nabila Marchoudi; Jamal Fekkak; Houda Benrahma; Chakib Nejjari; Saaid Amzazi; Lahcen Belyamani; Azeddine Ibrahimi
Journal:  PLoS One       Date:  2020-11-10       Impact factor: 3.240

Review 10.  Cytokine storm induced by SARS-CoV-2.

Authors:  Peipei Song; Wei Li; Jianqin Xie; Yanlong Hou; Chongge You
Journal:  Clin Chim Acta       Date:  2020-06-10       Impact factor: 6.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.